Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Hideko Isozaki(Massachusetts General Hospital), Aaron N. Hata(Harvard University)
Cited by 143
Related Papers
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
|Cancer Discovery|2019|238
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
|Cancer Discovery|2018|216
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
|Cell Metabolism|2023|142